MR guided focused ultrasound for high risk and recurrent breast cancer

Charlie C.M. Ma; L. Chen; G. Freedman; R. Bleicher

doi:10.1007/978-3-642-03906-5_38

MR guided focused ultrasound for high risk and recurrent breast cancer

Charlie C.M. Ma, L. Chen, G. Freedman, R. Bleicher

Fox Chase Cancer Center

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

4 Scopus citations

Abstract

In this work we investigate the feasibility of MR guided focused ultrasound (MRgFUS) as an alternative treatment modality for high risk and recurrent breast cancers to replace surgery and/or RT. Preliminary in vitro and in vivo experiments have demonstrated the ability of MRgFUS to ablate various tissues in well defined treatment volumes with an array of sonications under real-time image guidance. Our MRgFUS system consists of an Insightec ExAblate 2000 high-intensity focused ultrasound (HIFU) system and a 1.5T GE MR scanner. This system has been FDA approved for the treatment of uterine fibroids clinically and is being investigated under local IRB approval for treating bone metastases, prostate and breast cancers and the enhancement of drug delivery for gene therapy and chemotherapy. A comprehensive quality assurance (QA) program has been developed for the safe and effective operation of the MRgFUS system including system commissioning, monthly and annual QA procedures and pre-treatment calibration. Optimal parameters have been derived for breast treatment. For high-risk patients MRgFUS is used to ablate small (< 2cm) tumor volumes in combination with radiotherapy and chemotherapy. Larger treatment volumes (plus a margin) are designed for recurrent breast cancers.

Original language	English
Title of host publication	World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy
Publisher	Springer Verlag
Pages	140-143
Number of pages	4
Edition	6
ISBN (Print)	9783642039058
DOIs	https://doi.org/10.1007/978-3-642-03906-5_38
State	Published - 2009
Event	World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy - Munich, Germany Duration: Sep 7 2009 → Sep 12 2009

Publication series

Name	IFMBE Proceedings
Number	6
Volume	25
ISSN (Print)	1680-0737

Conference

Conference	World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy
Country/Territory	Germany
City	Munich
Period	09/7/09 → 09/12/09

Keywords

Breast cancer
Focused ultrasound
HIFU
MRI
MRgFUS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-642-03906-5_38

Cite this

Ma, C. C. M., Chen, L., Freedman, G., & Bleicher, R. (2009). MR guided focused ultrasound for high risk and recurrent breast cancer. In World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy (6 ed., pp. 140-143). (IFMBE Proceedings; Vol. 25, No. 6). Springer Verlag. https://doi.org/10.1007/978-3-642-03906-5_38

@inproceedings{9cf3286d4cf3450bab353166b7efe2ea,

title = "MR guided focused ultrasound for high risk and recurrent breast cancer",

abstract = "In this work we investigate the feasibility of MR guided focused ultrasound (MRgFUS) as an alternative treatment modality for high risk and recurrent breast cancers to replace surgery and/or RT. Preliminary in vitro and in vivo experiments have demonstrated the ability of MRgFUS to ablate various tissues in well defined treatment volumes with an array of sonications under real-time image guidance. Our MRgFUS system consists of an Insightec ExAblate 2000 high-intensity focused ultrasound (HIFU) system and a 1.5T GE MR scanner. This system has been FDA approved for the treatment of uterine fibroids clinically and is being investigated under local IRB approval for treating bone metastases, prostate and breast cancers and the enhancement of drug delivery for gene therapy and chemotherapy. A comprehensive quality assurance (QA) program has been developed for the safe and effective operation of the MRgFUS system including system commissioning, monthly and annual QA procedures and pre-treatment calibration. Optimal parameters have been derived for breast treatment. For high-risk patients MRgFUS is used to ablate small (< 2cm) tumor volumes in combination with radiotherapy and chemotherapy. Larger treatment volumes (plus a margin) are designed for recurrent breast cancers.",

keywords = "Breast cancer, Focused ultrasound, HIFU, MRI, MRgFUS",

author = "Ma, {Charlie C.M.} and L. Chen and G. Freedman and R. Bleicher",

year = "2009",

doi = "10.1007/978-3-642-03906-5_38",

language = "English",

isbn = "9783642039058",

series = "IFMBE Proceedings",

publisher = "Springer Verlag",

number = "6",

pages = "140--143",

booktitle = "World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy",

address = "Germany",

edition = "6",

note = "World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy ; Conference date: 07-09-2009 Through 12-09-2009",

}

Ma, CCM , Chen, L, Freedman, G & Bleicher, R 2009, MR guided focused ultrasound for high risk and recurrent breast cancer. in World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy. 6 edn, IFMBE Proceedings, no. 6, vol. 25, Springer Verlag, pp. 140-143, World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy, Munich, Germany, 09/7/09. https://doi.org/10.1007/978-3-642-03906-5_38

MR guided focused ultrasound for high risk and recurrent breast cancer. / Ma, Charlie C.M.; Chen, L.; Freedman, G. et al.
World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy. 6. ed. Springer Verlag, 2009. p. 140-143 (IFMBE Proceedings; Vol. 25, No. 6).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - MR guided focused ultrasound for high risk and recurrent breast cancer

AU - Ma, Charlie C.M.

AU - Chen, L.

AU - Freedman, G.

AU - Bleicher, R.

PY - 2009

Y1 - 2009

N2 - In this work we investigate the feasibility of MR guided focused ultrasound (MRgFUS) as an alternative treatment modality for high risk and recurrent breast cancers to replace surgery and/or RT. Preliminary in vitro and in vivo experiments have demonstrated the ability of MRgFUS to ablate various tissues in well defined treatment volumes with an array of sonications under real-time image guidance. Our MRgFUS system consists of an Insightec ExAblate 2000 high-intensity focused ultrasound (HIFU) system and a 1.5T GE MR scanner. This system has been FDA approved for the treatment of uterine fibroids clinically and is being investigated under local IRB approval for treating bone metastases, prostate and breast cancers and the enhancement of drug delivery for gene therapy and chemotherapy. A comprehensive quality assurance (QA) program has been developed for the safe and effective operation of the MRgFUS system including system commissioning, monthly and annual QA procedures and pre-treatment calibration. Optimal parameters have been derived for breast treatment. For high-risk patients MRgFUS is used to ablate small (< 2cm) tumor volumes in combination with radiotherapy and chemotherapy. Larger treatment volumes (plus a margin) are designed for recurrent breast cancers.

AB - In this work we investigate the feasibility of MR guided focused ultrasound (MRgFUS) as an alternative treatment modality for high risk and recurrent breast cancers to replace surgery and/or RT. Preliminary in vitro and in vivo experiments have demonstrated the ability of MRgFUS to ablate various tissues in well defined treatment volumes with an array of sonications under real-time image guidance. Our MRgFUS system consists of an Insightec ExAblate 2000 high-intensity focused ultrasound (HIFU) system and a 1.5T GE MR scanner. This system has been FDA approved for the treatment of uterine fibroids clinically and is being investigated under local IRB approval for treating bone metastases, prostate and breast cancers and the enhancement of drug delivery for gene therapy and chemotherapy. A comprehensive quality assurance (QA) program has been developed for the safe and effective operation of the MRgFUS system including system commissioning, monthly and annual QA procedures and pre-treatment calibration. Optimal parameters have been derived for breast treatment. For high-risk patients MRgFUS is used to ablate small (< 2cm) tumor volumes in combination with radiotherapy and chemotherapy. Larger treatment volumes (plus a margin) are designed for recurrent breast cancers.

KW - Breast cancer

KW - Focused ultrasound

KW - HIFU

KW - MRI

KW - MRgFUS

UR - http://www.scopus.com/inward/record.url?scp=77949353738&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-03906-5_38

DO - 10.1007/978-3-642-03906-5_38

M3 - Conference contribution

SN - 9783642039058

T3 - IFMBE Proceedings

SP - 140

EP - 143

BT - World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy

PB - Springer Verlag

T2 - World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy

Y2 - 7 September 2009 through 12 September 2009

ER -

MR guided focused ultrasound for high risk and recurrent breast cancer

Abstract

Publication series

Conference

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this